We have heard much over the last decade or so about the impact of the microbiome on responses to hematopoeitic stem cell transplant (HSCT) and checkpoint blockade, but what about other immunotherapies such as CAR-T cells?

This could well be one of the unexpected X factors accounting for some of the differences in outcomes seen in clinical trials in this niche.

Increasingly, scientists and physicians are starting to see how we really might be what we eat as well as how diet might impact response to therapeutic intervention.

How then should we go about learning more about this issue and – and just as importantly – figuring out the next steps to improve function ahead of such treatment in order to maximise the survival outcomes for patients undergoing stem cell or CAR-T cell therapies?

To learn more about progress, we interviewed one of the pioneers in this field to see what he had to say…

To continue reading our latest highlights on oncology new product development, including expert commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by